VirMedica, Inc., a leading provider of technology solutions designed to optimize the commercialization of specialty pharmaceutical products, announced that it has made a significant capital investment in D2 Pharma Consulting, LLC (“D2”). D2 is an independent consulting firm offering a broad range of commercialization services for manufacturers and service providers in the life sciences industry.
“D2 has a proven track record of excellence in providing a variety of collaborative consulting and advisement services to specialty manufacturers of all sizes,” stated Mark K. Barnes, Chairman and Chief Executive Officer of VirMedica. “As a technology business, VirMedica will benefit from D2’s in-depth market understanding of the critical challenges facing our mutual customer base.”
Based in St. Louis, D2 has advised on a significant number of U.S. pharmaceutical product launches over the last six years including specialty pharmaceutical, traditional pharmaceutical and medical device products. In addition, D2 works with many organizations including manufacturers, specialty pharmacies and industry solution providers to develop and implement unique operational solutions for specialty pharmaceuticals. While continuing to operate D2 as an autonomous consulting entity, Dean P. Erhardt, President, sees strong strategic value in the new relationship. “Not only does this transaction secure additional growth capital for D2, but also through our independent consulting engagements, we can deliver valuable insights to VirMedica’s executive team. This insight will significantly elevate the team’s understanding of the ever-changing market dynamics of specialty products. In turn, our specialty-manufacturing clients will benefit from new technology that is capable of supporting the complex nature of access services for specialty products.”
Filed Under: Drug Discovery